[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-542049-105":59,"doc-detail-542049-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","chronic-inflammatory-demyelinating-polyradiculoneuropathy-review-article-cardinal-clinical-electrophysiologic-and-treatment-features","Chronic Inflammatory Demyelinating Polyradiculoneuropathy - Review Article - Cardinal Clinical, Electrophysiologic, and Treatment Features","","This review article explains the cardinal clinical, electrophysiologic, and supportive features of typical chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and its variants, and provides guidance for applying simplified diagnostic criteria to distinguish CIDP from possible CIDP. It summarizes objective measures useful for monitoring patients and overviews current and emerging therapies. The article highlights how novel treatments and standardized outcomes can reduce misdiagnosis and delay, improving diagnostic precision while balancing efficacy, safety, and cost.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/chronic-inflammatory-demyelinating-polyradiculoneuropathy-review-article-cardinal-clinical-electrophysiologic-and-treatment-features/542049/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/chronic-inflammatory-demyelinating-polyradiculoneuropathy-review-article-cardinal-clinical-electrophysiologic-and-treatment-features/542049.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-16","2026-10-10",true,{"@type":102,"interactionType":103,"userInteractionCount":81},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are the key diagnostic elements for CIDP discussed in this article?","Question",{"text":112,"@type":113},"CIDP diagnosis relies on identifying cardinal clinical features and electrophysiologic evidence of peripheral nerve demyelination, using supportive data when needed, and excluding mimics. Because CIDP lacks a specific diagnostic biomarker, guideline-based diagnostic precision is emphasized.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How have CIDP diagnostic criteria been simplified?",{"text":117,"@type":113},"The diagnostic criteria have been simplified to a diagnosis of either CIDP or possible CIDP, rather than using a broader variant framework. The article also notes that chronic inflammatory sensory polyradiculoneuropathy is no longer considered a CIDP variant.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatments are highlighted for CIDP and what recent development is mentioned?",{"text":121,"@type":113},"Treatments include intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin, corticosteroids, and plasmapheresis. The article reports that subcutaneous efgartigimod alfa was approved by the FDA in June 2024 for CIDP, and that complement inhibition is being explored in clinical trials.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},542049,1791994670,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":81,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","REVIEW ARTICLE  \nCONTINUUM AUDIO INTERVIEW AVAI LABLEON LINE  \nCONTINUUM ALOUD RECORDING AVAI LAB LEON LINE  \nC ITE AS :  \nCONTINUUM (MIN NEA P M INN) 2026;32(5, PERIPHERAL NERVE AND MOTOR NEURON DISORDERS):1416–1439.  \nAddress correspondence to Dr Arjun Seth, 710 North Lake Shore Dr, Office 1112, Chicago, IL 60611, [arjun.seth@nm.org](arjun.seth@nm.org).  \nRELATIONSHIP DISCLOSURE: Dr Seth has received personal compensation in the range of $500 to $4999 for serving as a consultant for argenx, Amgen Inc, Johnson & Johnson, and Sanofi , and in the range of Continued on page 1439  \nUNLABELED USE OF PRODUCTS/ INVESTIGATIONAL USE DISCLOSURE:  \nDrs Seth and Allen discuss the off-label use of rituximab for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) .  \nAll cases in this article are hypothetical or composite.  \n© 2026 American Academy of Neurology.  \nChronic Infl ammatory Demyelinating Polyradiculoneuropathy  \nBy Arjun Seth, MD; Jeffrey A. Allen, MD  \nABSTRACT  \nOBJECTIVE: This article describes the cardinal clinical, electrophysiologic, and supportive features of typical CIDP and its variants, how to review and apply CIDP diagnostic criteria, objective measures that can be used in practice to follow patients with CIDP, and current and emerging treatment practices.  \nLATEST DEVELOPMENTS: The diagnostic criteria for CIDP have been simplified to a diagnosis of either CIDP or possible CIDP. Chronic inflammatory sensory polyradiculoneuropathy is no longer considered a variant of CIDP. Autoimmune nodopathies are considered a separate entity with some clinical and electrodiagnostic features similar to CIDP. Treatments include IV immunoglobulin (IVIg), subcutaneous immunoglobulin, corticosteroids, and plasmapheresis. Subcutaneous efgartigimod alfa, a neonatal Fc-receptor antagonist, was approved by the US Food and Drug Administration (FDA) in June 2024 for the treatment of CIDP, the first novel treatment by drug class for this condition. Complement inhibition is currently being explored in clinical trials for the treatment of CIDP.  \nESSENTIAL POINTS: CIDP is a rare, treatable neuropathy that is frequently misdiagnosed. As novel therapeutics are studied and approved for clinical use, special attention to the diagnostic criteria and the use of objective treatment outcome measures are essential to preventing misdiagnosis and ensuring that patients receive appropriate therapies.  \nINTRODUCTION  \nC  \nhronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated peripheral nerve disorder characterized clinically by progressive or relapsing motor and sensory deficits that evolve over at least 2 months and electrophysiologically by evidence of peripheral nerve  \ndemyelination on nerve conduction studies.1 The disorder is a syndrome, with a “typical” phenotype and variants that are still considered CIDP but with clinical features that vary in modality (sensory or motor symptom predominance) or region of the body affected (generalized, distal, or asymmetric) .1 The syndrome’s heterogeneity raises controversy over which variants should be included under the CIDP umbrella and which are distinct  \n1416 OCTOBER 2026  \nCopyright © 2026 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.  \nenough to warrant a separate classification. Between 1.0 and 8.9 people per 100,000 are affected by CIDP,2 of whom 60% to 80% manifest the typical form, while 20% to 40% harbor one of the recognized variants.3  \nConsidering that CIDP does not have a specific diagnostic biomarker, combined with the rarity and clinical heterogeneity of the condition, it is no surprise that both misdiagnosis and delayed diagnosis are common.4-6 The treatable nature of CIDP underscores the importance of early and accurate diagnosis, especially as new CIDP therapeutics become available. Equally important is the need for diagnostic precision to prevent unnecessary exposure of patients without CIDP to immuno","cbCaieNZcSHrnHa5","https://ap.wps.com/l/cbCaieNZcSHrnHa5","pdf",731753,24,"English","# Abstract\n# Introduction\n# Diagnostic Features\n## Clinical Characteristics of Typical CIDP\n## Diagnostic Approach: Clinical and Electrophysiologic Features\n## Avoiding Misdiagnosis and Delayed Diagnosis\n# Treatment Practices and Latest Developments","[{\"question\":\"What are the key diagnostic elements for CIDP discussed in this article?\",\"answer\":\"CIDP diagnosis relies on identifying cardinal clinical features and electrophysiologic evidence of peripheral nerve demyelination, using supportive data when needed, and excluding mimics. Because CIDP lacks a specific diagnostic biomarker, guideline-based diagnostic precision is emphasized.\"},{\"question\":\"How have CIDP diagnostic criteria been simplified?\",\"answer\":\"The diagnostic criteria have been simplified to a diagnosis of either CIDP or possible CIDP, rather than using a broader variant framework. The article also notes that chronic inflammatory sensory polyradiculoneuropathy is no longer considered a CIDP variant.\"},{\"question\":\"What treatments are highlighted for CIDP and what recent development is mentioned?\",\"answer\":\"Treatments include intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin, corticosteroids, and plasmapheresis. The article reports that subcutaneous efgartigimod alfa was approved by the FDA in June 2024 for CIDP, and that complement inhibition is being explored in clinical trials.\"}]","Chronic Inflammatory Demyelinating Polyradiculoneuropathy - Review Article - Cardinal Clinical, Electrophysiologic, and Treatment Features | PDF",1791669175]